Trial Profile
A safety and efficacy trial of liposomal amphotericin B (AmBisome) Patients with post kala-azar dermal leishmaniasis in India and Bangladesh.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Amphotericin B liposomal (Primary)
- Indications Visceral leishmaniasis
- Focus Adverse reactions; Therapeutic Use
- 13 Apr 2016 New trial record
- 05 Mar 2016 Results presented at the 17th International Congress on Infectious Diseases